Hidden RNA Molecule Drives Ovarian Cancer Growth by Activating Key Stress Pathway

Ovarian cancer remains one of the most lethal gynecological malignancies, largely because it tends to be diagnosed at advanced stages and because the molecular engines driving its growth and spread are still incompletely understood. Now, a team of researchers based at Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, together with a colleague at Shanghai General Hospital, has identified a long non-coding RNA molecule that appears to act as a powerful accelerant of the disease. The molecule, known as ATP6V1B1-AS1, was found to be elevated in ovarian cancer tissues, to correlate with poorer patient outcomes, and to fuel tumor proliferation and metastasis by physically engaging a signaling protein called MAP3K3 and switching on the p38 MAPK pathway. The findings, published in the Journal of Ovarian Research, point to a previously underappreciated regulatory axis that could become a target for new therapies.

Long non-coding RNAs, or lncRNAs, are RNA molecules longer than roughly two hundred nucleotides that are transcribed from the genome but are not translated into proteins. For decades they were dismissed as transcriptional noise, yet it is now clear that many of them perform sophisticated regulatory duties inside cells. Some act as molecular scaffolds, bringing proteins together into functional complexes; others serve as guides, escorting proteins to specific DNA regions; still others function as sponges that soak up microRNAs. In cancer biology, lncRNAs have emerged as master regulators that can tilt the balance between cell growth and cell death, and between tissue stability and invasive spread. The Suzhou-led team set out to determine whether ATP6V1B1-AS1, an lncRNA named for its genomic neighbor in the ATP6V1B1 gene region, plays such a role in ovarian cancer.

To establish the clinical relevance of the molecule, the researchers first examined its expression pattern using data from The Cancer Genome Atlas, a large public repository of tumor genomic profiles, and then confirmed their observations in patient samples using reverse transcription quantitative polymerase chain reaction, a sensitive technique for measuring RNA abundance. The results were consistent: ATP6V1B1-AS1 was upregulated in ovarian cancer compared with normal tissue, and higher levels of the RNA were associated with worse prognosis in patients. This kind of correlation does not by itself prove causation, but it provided the essential starting hypothesis that the molecule might be doing something more than merely marking the presence of aggressive disease.

The team then moved from correlation to function. Using laboratory-grown ovarian cancer cells, they silenced ATP6V1B1-AS1 and measured the consequences with a battery of standard assays. Cell counting kit 8 assays, which quantify metabolic activity as a proxy for the number of living cells, showed that silencing the RNA slowed proliferation. Colony formation assays, which test whether single cells can divide repeatedly to form visible colonies, revealed a reduced capacity for sustained growth. Migration assays demonstrated that the cells also lost much of their ability to move, a property that is central to cancer’s ability to invade surrounding tissue and seed distant organs. Together, these in vitro experiments suggested that ATP6V1B1-AS1 is not a passive bystander but an active contributor to the malignant behavior of ovarian cancer cells.

To verify that these effects hold true in living organisms rather than only in culture dishes, the researchers turned to animal models. They used xenograft models, in which human ovarian cancer cells are implanted into immunodeficient nude mice, allowing human tumors to grow in a living host. They also established lung metastasis models to track the spread of cancer cells to secondary sites. When ATP6V1B1-AS1 was silenced, the mice developed smaller tumors and showed reduced metastatic colonization of the lungs. This in vivo confirmation is a critical step, because the three-dimensional architecture, nutrient gradients, and immune-free but otherwise complex environment of a living animal can expose dependencies that simple cell culture misses. The results indicated that the RNA’s influence on tumorigenesis and metastasis is robust enough to manifest in a whole organism.

With the functional role established, the central question became mechanistic: how does a non-coding RNA accomplish all of this? The team’s answer came from an unbiased search for binding partners. They performed an RNA pull-down experiment, in which the ATP6V1B1-AS1 molecule is used as bait to capture proteins that physically associate with it inside cells. The captured proteins were then identified by liquid chromatography coupled with tandem mass spectrometry, a technique that reads out the molecular weights and sequences of peptides to determine which proteins are present. Among the hits was MAP3K3, also known as MEK kinase 3, a mitogen-activated protein kinase kinase kinase that sits near the top of a signaling cascade controlling the p38 MAPK pathway, a route well known for transmitting stress and inflammatory signals into the cell nucleus.

The interaction between ATP6V1B1-AS1 and MAP3K3 was further validated by co-immunostaining and Western blotting, which confirmed that the RNA and the protein occupy overlapping cellular compartments and that their association has measurable biochemical consequences. Specifically, the binding of ATP6V1B1-AS1 to MAP3K3 facilitated the phosphorylation of p38 MAPK, the chemical modification that activates this pathway. Phosphorylation acts like a molecular switch: when p38 MAPK is phosphorylated, it relays signals that can promote cell survival, proliferation, and motility. Rescue experiments, in which the researchers restored pathway activity after silencing the RNA, demonstrated that the effects of ATP6V1B1-AS1 loss could be traced back through MAP3K3 to p38 MAPK, establishing a coherent signaling axis: ATP6V1B1-AS1 binds MAP3K3, MAP3K3 drives p38 MAPK phosphorylation, and the activated pathway propels ovarian cancer progression.

The significance of this work lies partly in its conceptual contribution to the growing recognition that lncRNAs can regulate cancer not only through gene expression but through direct protein interactions that modulate signaling cascades. Rather than changing how much MAP3K3 is produced, ATP6V1B1-AS1 appears to change what MAP3K3 does, enhancing its ability to activate p38 MAPK. This mode of action is attractive from a therapeutic standpoint because it suggests that disrupting the RNA-protein interaction, rather than blocking the kinase itself, might achieve a similar effect with potentially fewer off-target consequences. It also adds ATP6V1B1-AS1 to a short list of lncRNAs implicated in ovarian cancer, a disease that urgently needs new molecular targets given the limited treatment options available once platinum-based chemotherapy fails.

The research was supported by the Basic Research Medical Applied Basic Research Project in Suzhou City and the Suzhou Applied Basic Research Healthcare Science and Technology Innovation Guiding Project, and it received ethics approval from the Research Ethics Committee of Suzhou Municipal Hospital and the Animal Ethics and Welfare Committee of Nanjing Medical University. The authors, led by Yan Zhang, Ting Chen, and Meng Liu as co-first authors, with Shunyu Hou and Ting Fu as corresponding authors, declare no competing interests. As with any preclinical study, the path from these findings to the clinic will require further validation in larger patient cohorts and the development of strategies to safely interfere with the ATP6V1B1-AS1/MAP3K3/p38 MAPK axis in humans. Nevertheless, the study offers a clear mechanistic blueprint for how a single non-coding RNA can orchestrate tumor growth and metastasis, and it may provide a potential therapeutic target for ovarian cancer at a time when such targets are sorely needed.

Subject of Research: The role of the long non-coding RNA ATP6V1B1-AS1 in promoting ovarian cancer progression via the MAP3K3/p38 MAPK signaling pathway

Article Title: Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway

Article References: Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway. (n.d.). https://doi.org/10.1186/s13048-026-02310-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02310-8

Keywords: ovarian cancer, long non-coding RNA, ATP6V1B1-AS1, MAP3K3, p38 MAPK, phosphorylation, metastasis, tumor progression, signal transduction, cancer biology, RNA-protein interaction, therapeutic target